BURLINGTON, Mass., Feb. 13, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that Michel Dubery will lead the European arm of the company's global communications division. Ranked by Advertising Age as the world's second largest healthcare agency network, inVentiv Health Communications (iHC) employs 1,800 professionals across the globe.

Dubery brings more than 30 years of broad, global healthcare industry experience to iHC, including specialized expertise in consumer and patient communication, relationship marketing, brand strategy development and business modeling. As Managing Director of inVentiv Health Communications/Europe (iHCE), he will oversee the agency's advertising and public relations offerings.

"iHCE's goal is to form strategic partnerships with clients that provide them with the necessary support to quickly maneuver in a complex world," said Bob Chandler, President, inVentiv Health Communications and Senior Vice President, Marketing and Communications, inVentiv Health. "Mounting pressures to limit healthcare costs across Europe are creating new communication challenges for our clients. Michel's vast knowledge of the market on a regional and global level will enhance our ability to help clients navigate this complicated landscape and reach patients and healthcare professionals in meaningful ways. We are delighted that he is joining us."

With operational headquarters in London that serves as a hub for all European offices, iHCE designs relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, helping clients excel in a challenging and rapidly changing environment. As part of iHC, iHCE operates under a "Done as One" business model that enables the convergence of inVentiv's best-in-class advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services. The model allows clients to bring their challenges to iHCE, which then assembles the cross-disciplinary expertise, services and team needed to deliver successful solutions. 

Prior to joining iHCE, Dubery served as Managing Director, Europe at Grey Healthcare Group. Under his leadership, the company's European business margins improved considerably, with the London office experiencing five-fold growth in less than four years. From 2007 to 2009, Dubery served as Chief Strategy Officer, Europe at DDB Health Group, where he redeveloped the agency's strategic offerings, including new tools and workshops. In addition to his role as Senior Planning Partner at WWAV Rapp Collins, Dubery has held several marketing positions at leading healthcare companies, including Novartis, Sandoz, Hoechst-Roussel and Astra Pharmaceuticals. Earlier in his career, Dubery was a staff nurse specializing in orthopedics at Burnley General Hospital in Lancashire, England.   

About inVentiv Health Communications/Europe
inVentiv Health Communications/Europe (iHCE) is the European arm of inVentiv Health Communications, the inVentiv Health division dedicated to delivering exceptional global, multichannel communications for organizations focused on health and wellness. iHCE provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment. The company's unified offer brings together inVentiv Health's advertising, public relations, public policy, market access, medical education, marketing, digital and branding services. iHCE is based in Switzerland with operational headquarters in London.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.    

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

SOURCE inVentiv Health, Inc.